Core Insights - The Trump administration's renewed focus on quantum policy through executive actions and the potential reauthorization of the National Quantum Initiative Act (NQIA) could significantly benefit both dedicated quantum firms and major tech companies investing in this sector [1][2]. Quantum Industry Developments - The White House is preparing up to three executive orders aimed at quantum information sciences and the transition to post-quantum cryptography (PQC), extending the momentum from the 2018 NQIA which expired in 2023 [2]. - Government mandates for PQC migration and increased R&D funding are expected to accelerate the adoption of quantum technologies, moving startups from research phases to practical applications [3][10]. Major Players in Quantum Technology - Companies like IBM, Google, and NVIDIA are already heavily invested in quantum technology, and the new directives validate their strategies, enhancing procurement pipelines and positioning them as key providers for a government-led quantum transition [5]. - IBM announced plans for the "Quantum Starling," a fault-tolerant system targeted for 2029, while Google introduced its Willow quantum chip, aiming for commercial applications within five years [6]. Stock Performance and Market Sentiment - Quantum-related stocks have seen a significant rally, with the Defiance Quantum ETF (QTUM) gaining 12.2% month-to-date as investors anticipate stronger federal support and faster adoption cycles [7]. - D-Wave reported an 83% year-over-year increase in APAC bookings, with its Advantage2 system now generally available, indicating strong market demand [11]. Company-Specific Insights - IonQ has expanded through acquisitions, targeting 2 million physical qubits by 2030, positioning itself to benefit from government PQC mandates [13]. - Rigetti has made advancements in its modular multi-chip systems and aims to deliver over 100 qubits by year-end, enhancing its potential for government contracts [15]. - D-Wave and IonQ both carry a Zacks Rank 3, with expected earnings growth of 68% and 37.88% respectively for 2025, alongside significant revenue increases [12][14].

Key Takeaways Nasdaq set new intra-day and closing highs, finishing the session at 22,788.98. NVIDIA, Broadcom and ACM Research stood out with high net income ratios.Screening narrowed 7,685 stocks to 74 using profitability and growth metrics.The Nasdaq broke records on Monday, reaching an all-time intraday high. The tech-heavy index also closed the trading session at a record high, finishing at 22,788.98. Hence, it’s judicious for astute investors to keep an eye on companies listed on the Nasdaq that deliv ...

Key Takeaways Finding the top-ranked momentum stocks to buy for October and beyond.Why this soaring, under-the-radar automotive equipment stock is a Zacks Rank #1 (Strong Buy).The stock market is trading at new all-time highs in the final full week of September and the third quarter. The recent surge has been driven by a wave of spending across the artificial intelligence ecosystem as investors, big and small, clamor to make sure they don’t get left behind if there is another huge leg up for Wall Street.Som ...

Core Insights - Ionis Pharmaceuticals announced positive topline results from a pivotal phase III study for its investigational RNA-targeted therapy zilganersen, aimed at treating Alexander disease (AxD) [1][4] Group 1: Study Results - The study met its primary endpoint, showing that patients receiving a 50 mg dose of zilganersen achieved a statistically significant 33.3% stabilization in gait speed compared to the control group, measured by the 10-Meter Walk Test (10MWT) [2] - Treatment with zilganersen demonstrated a favorable safety and tolerability profile, with consistent benefits observed across key secondary endpoints, indicating evidence of slowed disease progression [3][9] Group 2: Regulatory and Market Implications - Ionis plans to submit a regulatory filing with the FDA for zilganersen in Q1 2026, marking it as the first investigational medicine to show a positive disease-modifying impact in AxD [6][4] - If approved, zilganersen will join Ionis' portfolio as the third wholly-owned drug, alongside Tryngolza and Dawnzera, which were approved in the last 12 months [7] Group 3: Financial Performance and Strategy - Year-to-date, Ionis shares have increased nearly 76%, significantly outperforming the industry growth of 12% [8] - Ionis has established collaborations with major pharmaceutical companies, providing funds through license fees and milestone payments to support the development of its wholly-owned pipeline [10] - The company earns commercial revenues from royalties on Spinraza and Qalsody, with ongoing partnerships for other drug developments [11][12]

Key Takeaways Palantir's AIP drove Q2 U.S. commercial revenues up 93% and contracts up 222% year over year.UiPath reported Q2 revenue growth of 14% to $362M, with ARR rising 11% to $1.72B.UiPath trades at 4.22X forward sales, far below Palantir's 82X, offering a more appealing entry point.Both Palantir Technologies Inc. (PLTR) and UiPath Inc. (PATH) stand out as leading innovators in AI-driven software.Palantir has built its reputation on large-scale data analytics and decision intelligence platforms, deliv ...

Core Viewpoint - OUTFRONT Media (OUT) has experienced a 16.2% increase in share price over the past three months, contrasting with a 1.3% decline in the industry, driven by its diversified advertising portfolio and transition to digital displays [1][7]. Group 1: Company Performance - OUTFRONT Media operates a diversified portfolio of advertising sites across major U.S. markets, allowing clients to reach a national audience while tailoring campaigns to specific regions [3]. - The company is transitioning from traditional static billboard advertising to digital displays, which is expected to enhance new advertising relationships and boost digital revenue [4]. - Strategic acquisitions have been made, with approximately $8.5 million spent on new assets in the six months ending June 30, 2025, positioning the company for long-term growth [5]. Group 2: Industry Context - The outdoor advertising industry has high barriers to entry due to permitting restrictions, with OUTFRONT Media owning valuable permits that support advertising rates and limit competition [8]. - The company's revenues are less volatile due to its large-scale presence and diversified portfolio across various industries, including professional services, healthcare, and retail [3]. Group 3: Future Outlook - Analysts are optimistic about OUTFRONT Media, with the Zacks Consensus Estimate for its 2025 FFO per share increasing to $1.89 [2]. - The ongoing investments in digital billboard technology and portfolio expansion are anticipated to drive revenue and OIBDA growth in the future [4][7].

Key Takeaways SouthState shares gained 11.6% in three months, beating industry and peers' performance. Fed rate cuts, NII growth, and acquisitions like Independent Bank boosted scale and margins.Strong liquidity supports dividend hikes and buybacks, though expenses and CRE risks weigh.SouthState Corporation’s (SSB)   shares have rallied 11.6% in the past three months, outperforming the industry’s growth of 6.8%. Further, the company has performed better than its peers, Origin Bancorp, Inc. (OBK) and Stock Y ...

Flanigan's Enterprises, Inc. (BDL) investors have been experiencing some short-term gains from the stock lately, despite its bumpy ride over recent months. Shares of the owners and operators of the "Flanigan's Seafood Bar and Grill" restaurants and "Big Daddy's" retail liquor stores, which is based in Fort Lauderdale, FL, have gained 37.7% in the past six months against the industry’s 8.1% decline. In the same time frame, the stock also outperformed the sector and the S&P 500’s 10.3% and 17.7% gains, respec ...

Key Takeaways ZTO's earnings estimates for 2025 have been revised lower, signaling weak broker confidence.ZTO cut its 2025 parcel volume forecast to 38.8-40.1 billion from the prior 40.8-42.2 billion.ZTO shares have lost 18.7% over the past year, underperforming the broader trucking industry.Shares of ZTO Express (ZTO)  have had an unimpressive run in a year. Shares of this company have plunged 18.7% in the same period, underperforming the transportation-services industry’s14.5% decline.ZTO Stock's One-Year ...

Group 1: Company Overview - Intel designs and manufactures a wide range of computer hardware and software products, primarily known for its microprocessors and graphics cards [1] - Founded in 1968 and based in Santa Clara, California, Intel plays a significant role in personal computers and servers, as well as in cloud computing and artificial intelligence [1] Group 2: Government and Financial Support - Intel was awarded an $11.1 billion grant under the CHIPS and Science Act, aimed at boosting domestic semiconductor manufacturing in the U.S. [2] - The Trump Administration secured a 9.9% equity stake in Intel for American taxpayers, indicating a vested interest in Intel's long-term success [3] Group 3: Strategic Investments - Nvidia announced a $5 billion investment in Intel, which is expected to enhance collaboration on AI and data centers, leading to a significant stock price increase of over 20% [4] - The investment from Nvidia, along with the U.S. government's stake, provides Intel with crucial support and confidence from key industry players [4] Group 4: Valuation Metrics - Intel's price-to-book ratio stands at 1.19x, making it relatively inexpensive compared to the S&P 500's average of approximately 4.6 [5] Group 5: Market Position and Growth - Intel is gaining traction in the AI infrastructure market, with partnerships like that with Super Micro Computer to deploy its technology for large-scale databases [10] - The acquisition of Mobileye positions Intel in the rapidly growing autonomous car technology market [10] Group 6: Future Outlook - Intel is on the verge of a significant turnaround, supported by government equity, Nvidia's investment, and its foundational role in AI, making it an attractive investment opportunity [11]